Mural Oncology granted stock options and restricted stock units to four new employees as part of their inducement plan.
Quiver AI Summary
Mural Oncology plc, a clinical-stage immuno-oncology company, announced on December 2, 2024, the granting of stock options and restricted stock units to four new employees as part of its 2024 Inducement Stock Option and Incentive Plan. The grants include a total of 26,300 stock options at an exercise price of $4.18 per share and 13,200 restricted stock units, intended to incentivize the new hires. The stock options have a ten-year term and vest over four years, along with similar vesting terms for the restricted stock units, both contingent on continued employment. Mural Oncology focuses on developing innovative cytokine therapies for cancer treatment, with its lead candidate, nemvaleukin, in trials for mucosal melanoma and platinum-resistant ovarian cancer.
Potential Positives
- The company is demonstrating growth and attracting talent by granting stock options and restricted stock units to newly hired employees, which can enhance employee retention and motivation.
- The inducement awards are a strategic move in compliance with Nasdaq regulations, showcasing the company's commitment to operate within established guidelines.
- By providing equity-based compensation, Mural Oncology aligns employee interests with the company's long-term performance, potentially fostering a culture of ownership and investment in the company's success.
- Mural Oncology's ongoing clinical trials for its lead candidate, nemvaleukin, indicates active development in the competitive oncology space, which could lead to significant breakthroughs in cancer treatment.
Potential Negatives
- Granting non-statutory stock options and restricted stock units may indicate a reliance on equity compensation to attract talent, suggesting potential difficulties in attracting or retaining employees through traditional compensation methods.
- The press release details stock options and restricted stock units for new hires, which may raise concerns about dilution of existing shareholders' equity if such stocks are exercised or vested in large quantities.
- The need to incentivize newly hired employees through stock options and restricted stock units may signal that the company is still in the early stages of its growth and may not yet be able to offer competitive salaries or benefits compared to more established firms in the industry.
FAQ
What stock options were granted by Mural Oncology?
Mural Oncology granted non-statutory stock options to purchase 26,300 ordinary shares to four newly hired employees.
What are the vesting terms for the stock options?
The stock options vest over four years, with 25% vesting on the first anniversary and 6.25% quarterly thereafter.
How many restricted stock units were granted?
The company granted restricted stock units for an aggregate of 13,200 ordinary shares as part of the inducement package.
What is Mural Oncology's main focus?
Mural Oncology focuses on developing novel engineered cytokine therapies for patients with various types of cancers.
Where is Mural Oncology headquartered?
Mural Oncology has its registered office in Dublin, Ireland, with primary facilities in Waltham, Massachusetts.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MURA Insider Trading Activity
$MURA insiders have traded $MURA stock on the open market 5 times in the past 6 months. Of those trades, 1 have been purchases and 4 have been sales.
Here's a breakdown of recent trading of $MURA stock by insiders over the last 6 months:
- VICKI L GOODMAN (Chief Medical Officer) sold 5,069 shares.
- ADAM D. CUTLER (Chief Financial Officer) sold 7,421 shares.
- SUSAN ALTSCHULLER purchased 10,000 shares.
- MAIKEN KESON-BROOKES (See Remarks) sold 2,157 shares.
- CAROLINE LOEW (Chief Executive Officer) sold 12,531 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MURA Hedge Fund Activity
We have seen 20 institutional investors add shares of $MURA stock to their portfolio, and 76 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 743,495 shares (-100.0%) from their portfolio in Q3 2024
- BAKER BROS. ADVISORS LP removed 222,503 shares (-100.0%) from their portfolio in Q2 2024
- VERITION FUND MANAGEMENT LLC removed 170,847 shares (-33.4%) from their portfolio in Q3 2024
- NORGES BANK removed 168,511 shares (-100.0%) from their portfolio in Q2 2024
- NUVEEN ASSET MANAGEMENT, LLC removed 161,917 shares (-100.0%) from their portfolio in Q2 2024
- GOLDMAN SACHS GROUP INC removed 129,421 shares (-72.1%) from their portfolio in Q3 2024
- POINT72 ASSET MANAGEMENT, L.P. added 108,715 shares (+inf%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on December 2, the Company granted to four newly hired employees (i) non-statutory stock options to purchase an aggregate of 26,300 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 13,200 ordinary shares of the Company, pursuant to the Company's 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $4.18 per share, which is equal to the closing price per share of the Company's ordinary shares as reported by Nasdaq on December 2, 2024. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the grant date and 6.25% of the shares underlying the options vesting quarterly thereafter, subject to such employee's continued service with the Company through the applicable vesting dates. Each of the stock options is subject to the terms and conditions of a stock option award agreement covering the grant and the Company's 2024 Inducement Stock Option and Incentive Plan. The restricted stock units vest over four years, 25% per year on the anniversary of the grant date, subject to such employee's continued service with the Company through the applicable vesting dates. Each of the restricted stock units is subject to the terms and conditions of a restricted stock award agreement covering the grant and the Company's 2024 Inducement Stock Option and Incentive Plan.
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential and reach of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin, is currently in potentially registrational trials in mucosal melanoma and platinum-resistant ovarian cancer. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology's website at
and follow us on
LinkedIn
and
X
.
Contact
Katie Sullivan
katie.sullivan@muraloncology.com
